

CITATION REPORT

List of articles citing

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

DOI: 10.1056/nejmoa1402355

New England Journal of Medicine, 2014, 370, 1879-88.

Source: <https://exaly.com/paper-pdf/58947468/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1050	Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. 2014 , 28, 445-51		51
1049	Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. 2014 , 28, 529-34		5
1048	CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfecting adults. 2014 , 25, 311-20		6
1047	Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir. 2014 , 59, 1675-7		2
1046	Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. 2014 , 12, 763-73		40
1045	Sofosbuvir as backbone of interferon free treatments. 2014 , 46 Suppl 5, S212-20		19
1044	The future of dual therapy for hepatitis C virus. 2014 , 9, 905-912		1
1043	[Treatment of hepatitis C: what is known?]. 2014 , 55, 1419-26		4
1042	Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. 2014 , 14, 503		3
1041	Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. 2014 , 61, S98-S107	25	
1040	"Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?. 2014 , 6, 1893-907		8
1039	Actualizaci3n en el tratamiento de la hepatitis C. 2014 , 11, 4103-4111		
1038	Optimal Management of HIV-HCV Coinfection. <i>Current Hepatology Reports</i> , 2014 , 13, 295-303	1	
1037	Recent advances in the prevention of hepatocellular carcinoma recurrence. 2014 , 34, 427-34		43
1036	Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. 2014 , 7, 387-98		18
1035	Antiviral Agents. 2014 , 176-176		
1034	Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. 2014 , 1, ofu110		44

1033	Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. 2014 , 161, 634-8		62
1032	[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Simeprevir-benefit assessment according to § 35a SGB V the Federal Joint Committee]. 2014 , 52, 1495-9		
1031	Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. 2014 , 52, 1185-1197		5
1030	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. 2014 , 384, 1953-97		371
1029	Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. 2014 , 15, 2609-22		17
1028	New all-oral HCV therapies for genotype 1: A final good-bye to interferon. 2014 , 3, 137-140		2
1027	Optimal Management of HCV Transplant Patients. <i>Current Hepatology Reports</i> , 2014 , 13, 304-313	1	
1026	A practical guide for antiviral therapy of chronic Hepatitis C. 2014 , 21, 221-230		6
1025	Management of acute and chronic HCV infection in persons with HIV coinfection. 2014 , 61, S108-19		15
1024	Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. 2014 , 34, 1341-54		25
1023	Daclatasvir for the treatment of hepatitis C virus infection. 2014 , 8, 725-38		6
1022	Hepatitis C genotype 1. 2014 , 27, 535-9		
1021	New expensive treatments for hepatitis C infection. 2014 , 312, 593-4		62
1020	Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. 2014 , 46 Suppl 5, S206-11		6
1019	Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. 2014 , 61, 435-8		32
1018	Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?. 2014 , 107, 119-24		32
1017	Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2014 , 370, 1889-98	59.2	1402
1016	Therapy of hepatitis C--back to the future. <i>New England Journal of Medicine</i> , 2014 , 370, 2043-7	59.2	91

1015	The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. 2014 , 46 Suppl 5, S186-96	53	
1014	Hepatitis C beware--the end is nigh. 2014 , 384, 1557-60	18	
1013	Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. 2014 , 61, S91-7	21	
1012	Oncogenes and RNA splicing of human tumor viruses. 2014 , 3, e63	32	
1011	Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus. 2014 , 66, 1653-66	18	
1010	Optimal Management of the Hepatitis C Patient: Review of the AASLD/IDSA Guidelines. <i>Current Hepatology Reports</i> , 2014 , 13, 314-320	1	
1009	Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. 2014 , 15, 1837-48	6	
1008	New therapies for hepatitis C: considerations in patients with renal impairment. 2014 , 74, 1307-13	4	
1007	Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. 2014 , 8, 352-64	1	
1006	Treatment of hepatitis C: perspectives. 2014 , 44, 449-54	11	
1005	Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. 2014 , 54, 1290-8	20	
1004	Hepatitis C: Treatment triumphs. 2014 , 510, 43-4	32	
1003	Sofosbuvir: a review of its use in patients with chronic hepatitis C. 2014 , 74, 1127-46	57	
1002	QUEST for a cure for hepatitis C virus: the end is in sight. 2014 , 384, 381-3	6	
1001	Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. 2014 , 61, 770-6	9	
1000	Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis. 2014 , 40, 351-7	15	
999	The clinical management of HCV in the HIV-infected patient. <i>Antiviral Therapy</i> , 2015 , 20, 457-67	1.6	2
998	Hepatitis C: from discovery to eradication. 2014 , 12, 26-35	2	

997	Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis. 2014 , 9, 679-692		
996	A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. <i>Antiviral Therapy</i> , 2015 , 20, 469-77	1.6	6
995	The dawn of a new era in the treatment of HCV infection: A view from the USA. 2014 , 4, 107-108		
994	[Cost-effective medical therapy of hepatitis C employing novel compensation models - pay for cure]. 2015 , 53, 1414-21		1
993	Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. <i>Hepatology</i> , 2015 , 62, 932-54	11.2	968
992	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. 2015 , 45, E115-21		35
991	HCV Kinetic Models and Their Implications in Drug Development. 2015 , 4, 231-42		13
990	Cancers in Australia in 2010 attributable to infectious agents. 2015 , 39, 446-51		23
989	Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. 2015 , 41, 497-520		130
988	A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 1011-9	3.4	48
987	Emerging options for treating hepatitis C infection. 2015 , 19, 183-7		1
986	Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor. 2015 , 61-80		4
985	Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. 2015 , 163, 215-23		304
984	Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. 2015 , 163, 899-907		46
983	Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection. <i>Antiviral Therapy</i> , 2016 , 21, 297-306	1.6	2
982	Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection. 2015 , 4, 33-5		10
981	The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. <i>Antiviral Therapy</i> , 2016 , 21, 185-94	1.6	5
980	MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. 2015 , 10, 25-52		19

979	Labour productivity losses caused by premature death associated with hepatitis C in Spain. 2015 , 27, 631-7		17
978	Self-reported need for psychotherapy predicts interferon-induced depression in hepatitis C: stratification for interferon-free treatment. <i>Antiviral Therapy</i> , 2015 , 20, 501-6	1.6	2
977	A new era of therapy for hepatitis C virus infection. 2015 , 28, 471-8		16
976	New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir. 2015 , 3, 2324709615623300		10
975	Hepatitis C □Therapie-Update. 2015 , 12, 7-16		
974	Interferonfreie Therapie der Hepatitis C mit/ohne nukleosidischen Polymeraseinhibitor. 2015 , 10, 292-296		
973	Therapie der Hepatitis C Virusinfektion. 2015 , 10, 61-72		
972	Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. 2015 , 25, 254-67		13
971	Treatment of hepatitis C in coinfecting patients. 2015 , 10, 1291-1305		
970	Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. 2015 , 15, 471		14
969	Impact of hepatitis C status on 20-year mortality of patients with substance use disorders. 2015 , 10, 20		2
968	Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. 2015 , 121, 2874-82		53
967	On computer-intensive simulation and estimation methods for rare-event analysis in epidemic models. 2015 , 34, 3696-713		
966	The hepatitis C revolution part 1: antiviral treatment options. 2015 , 28, 563-71		16
965	Harvoni (ledipasvir and sofosbuvir) for hepatitis C. 2015 , 40, 22-6		4
964	The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. 2015 , 42, 286-95		74
963	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. 2015 , 16, 599-607		5
962	Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011. 2015 , 10, 608-14		15

961	Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 906-13	3.4	19
960	Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 861-70	3.4	64
959	Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. 2015 , 10, 337-47		11
958	Recent advances in management of the HIV/HCV coinfecting patient. 2015 , 10, 981-997		4
957	Changing the face of hepatitis C management - the design and development of sofosbuvir. 2015 , 9, 2367-74		20
956	Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. 2015 , 16, 18439-53		18
955	Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. 2015 , 7, 1843-55		24
954	Management of Hepatitis C in the Indian Context: An Update. 2015 , 04,		3
953	Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. 2015 , 6, 114-9		10
952	Sofosbuvir, a Significant Paradigm Change in HCV Treatment. 2015 , 3, 27-35		45
951	New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo. 2015 , 21, S1-14		7
950	Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. <i>Viruses</i> , 2015 , 7, 5155-68	6.2	19
949	Interferon-free combination therapies for the treatment of hepatitis C: current insights. 2015 , 7, 51-70		46
948	Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. <i>Viruses</i> , 2015 , 7, 5206-24	6.2	81
947	Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. 2015 , 11, e1004040		16
946	Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. 2015 , 10, e0134395		64
945	Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production. 2015 , 10, e0135232		5
944	Presence of Rheumatoid Factor during Chronic HCV Infection Is Associated with Expansion of Mature Activated Memory B-Cells that Are Hypo-Responsive to B-Cell Receptor Stimulation and Persist during the Early Stage of IFN Free Therapy. 2015 , 10, e0144629		7

943	Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naŕe Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. 2015 , 10, e0145953	45
942	Treatment guidelines for Hepatitis C in Spain. 2015 , 17, 37-47	2
941	Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfecteĖ patients are comparable with hepatitis C monoinfected patients. 2015 , 26, 293-6	3
940	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. 2015 , 2015, 159795	5
939	An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. 2015 , 29, 19-34	59
938	Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. 2015 , 2015, 852968	5
937	The dollars and sense of chronic hepatitis C infection management. 2015 , 26, 119-21	1
936	The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. 2015 , 29, 46-8	4
935	Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada. 2015 , 29, 125-9	4
934	Viral Hepatitis. 2015 , 1439-1468.e7	4
933	Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin. 2015 , 14, 132-136	4
932	Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. 2015 , 14, S7-S48	0
931	Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. 2015 , 7, 1921-35	10
930	[New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent]. 2015 , 66, 5-9	1
929	HCV cure for everyone or which challenges remain?. <i>Journal of Virus Eradication</i> , 2015 , 1, 55-58	2.8 3
928	Hepatitis C [Overview and Update in Treatment. 2015 ,	
927	Advances in HCV Therapy. 2015 ,	
926	New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies. 2015 ,	

925	Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. 2015 , 16, 739-48		11
924	Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. 2015 , 29, 379-83		29
923	Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. 2015 , 37, 698-708		12
922	Global policy and access to new hepatitis C therapies for people who inject drugs. 2015 , 26, 1064-71		12
921	Hepatitis C Infection in the Elderly. 2015 , 60, 3170-80		29
920	Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. <i>Hepatology</i> , 2015 , 61, 1471-8	11.2	42
919	Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. 2015 , 75, 675-85		54
918	Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. 2015 , 14, 1317-26		16
917	Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?. 2015 , 7, 11-20		2
916	Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C. 2015 , 2, ofv057		2
915	Implementation of the Lancet Standing Commission on Liver Disease in the UK. 2015 , 386, 2098-2111		47
914	The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. 2015 , 10, 1363-77		43
913	HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015. <i>Current Hepatology Reports</i> , 2015 , 14, 260-266	1	
912	Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). 2015 , 32, 1117-27		24
911	Hepatitis C: pay now or pay later?. 2015 , 10, 1285-1290		
910	[Hepatitis C]. 2015 , 157 Spec No 2, 86-9; quiz 90		
909	The treatment of infectious disease with a medical device: results of a clinical trial of ultraviolet blood irradiation (UVBI) in patients with hepatitis C infection. 2015 , 37, 58-63		5
908	Effect of IL28B genotype on hepatitis B and C virus infection. 2015 , 14, 50-5		17

907	Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia. 2015 , 12, 84		11
906	Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. 2015 , 49, 343-50		20
905	Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. <i>Liver International</i> , 2015 , 35 Suppl 1, 65-70	7.9	16
904	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. 2015 , 70, 197-205		33
903	Viral hepatitis: towards the eradication of HCV and a cure for HBV. <i>Liver International</i> , 2015 , 35 Suppl 1, 1-3	7.9	
902	Hepatitis C. 2015 , 385, 1124-35		365
901	Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection. <i>Liver International</i> , 2015 , 35 Suppl 1, 56-64	7.9	23
900	Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. 2015 , 49, 566-81		37
899	Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. 2015 , 14, 473-84		8
898	Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. 2015 , 41, 544-63		96
897	Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. <i>Hepatology</i> , 2015 , 61, 1798-808	11.2	109
896	Bioactive nucleoside analogues possessing selected five-membered azaheterocyclic bases. 2015 , 97, 409-18		26
895	Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. <i>Hepatology</i> , 2015 , 61, 1747-54	11.2	12
894	Sofosbuvir for treatment of chronic hepatitis C. 2015 , 9, 161-73		22
893	Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. 2015 , 37, 243-67		24
892	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. <i>Liver International</i> , 2015 , 35, 1845-52	7.9	19
891	Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?. 2015 , 9, 559-66		13
890	Shorter treatments for hepatitis C: another step forward?. 2015 , 385, 1054-5		4

889	Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. 2015 , 385, 1107-13	131
888	Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. 2015 , 148, 468-79	41
887	Is widespread screening for hepatitis C justified?. 2015 , 350, g7809	31
886	Innate and adaptive genetic pathways in HCV infection. 2015 , 85, 231-40	11
885	Revolution in hepatitis C antiviral therapy. 2015 , 113, 31-44	29
884	Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C. 2015 , 16, 801-4	5
883	Cost-effectiveness of screening for hepatitis C in Canada. 2015 , 187, E110-E121	50
882	Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. 2015 , 30, 1197-204	32
881	Hepatitis C virus therapeutic development: in pursuit of "perfectovir". 2015 , 60, 1829-36	105
880	Enhancing our understanding of current therapies for hepatitis C virus (HCV). 2015 , 12, 68-78	25
879	Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. 2015 , 110, 1179-85	32
878	The New Era of Interferon-Free Treatment of Chronic Hepatitis C. 2015 , 31, 290-6	14
877	A pill a day keeps HCV away. 2015 , 15, 616-7	8
876	Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. 2015 , 49, 1015-30	12
875	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. 2015 , 8, 298-312	83
874	Chronic hepatitis B: A wave of new therapies on the horizon. 2015 , 121, 69-81	53
873	HCV targeting of patients with cirrhosis. 2015 , 63, 1015-22	42
872	Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. 2015 , 63, 1103-10	52

871	Clinical Applications of Quantitative Real-Time PCR in Virology. 2015 , 42, 161-197		1
870	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015 , 373, 714-25	59.2	337
869	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015 , 373, 705-13	59.2	382
868	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. 2015 , 149, 971-80.e1		67
867	Paritaprevir in patients with chronic hepatitis C genotype 1. 2015 , 10, 679-690		1
866	An overview of new biomolecular pathways in pathogen-related cancers. 2015 , 11, 1625-39		11
865	HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. 2015 , 61, 1127-34		26
864	Advances in Hepatitis C Treatment: At the Crossroads. 2015 , 11, 669-679		1
863	Ledipasvir/Sofosbuvir. 2015 , 50, 224-34		5
862	Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C. 2015 , 11, 1157-65		1
861	Modelling hepatitis C therapy--predicting effects of treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 437-45	24.2	55
860	Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. 2015 , 29, 329-37		9
859	Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. 2015 , 15, 645-53		294
858	Treatment of hepatitis C in difficult-to-treat patients. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 284-92	24.2	60
857	From non-A, non-B hepatitis to hepatitis C virus cure. 2015 , 62, S87-99		231
856	Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. 2015 , 67, 67-72		17
855	[Treatment of hepatitis C]. 2015 , 56, 391-405		1
854	Novel interventions to prevent HIV and HCV among persons who inject drugs. 2015 , 12, 145-63		16

853	Cure of HCV related liver disease. <i>Liver International</i> , 2015 , 35 Suppl 1, 71-7	7.9	20
852	Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. 2015 , 62, 1256-64		50
851	EASL Recommendations on Treatment of Hepatitis C 2015. 2015 , 63, 199-236		942
850	Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi. 2015 , 37, 1092-112		6
849	Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. 2015 , 162, 407-19		159
848	Interferon-free therapy for hepatitis C: The hurdles amid a golden era. 2015 , 47, 727-33		10
847	Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. 2015 , 4, 267-277		9
846	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015 , 62, 25-30	11.2	71
845	Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. 2015 , 63, 337-45		116
844	Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. 2015 , 163, 1-13		425
843	The cancer burden attributable to biologic agents. 2015 , 25, 183-7		21
842	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. 2015 , 385, 2502-9		220
841	Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. 2015 , 162, 397-406		263
840	Management of post transplant hepatitis C in the direct antiviral agents era. 2015 , 9, 192-201		7
839	Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. 2015 , 313, 1232-9		171
838	HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. 2015 , 9, 424-30		29
837	Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. 2015 , 47, 555-62		31
836	[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA]. 2015 , 53, 519-23		

835	[S2k Guideline non-alcoholic fatty liver disease]. 2015 , 53, 668-723	85
834	Hepatitis C Virus: A European Perspective. 2015 , 44, 807-24	12
833	Ledipasvir/sofosbuvir in chronic hepatitis C: a guide to its use in the EU. 2015 , 31, 289-295	2
832	Overtreating versus undertreating: what is the optimized treatment duration in HCV?. 2015 , 10, 1049-1056	
831	Advances in hepatitis C therapies. 2015 , 16, 1929-43	2
830	Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. 2015 , 14, 1421-34	13
829	Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012. 2015 , 21, 186-8	7
828	Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection. 2015 , 15, 993-995	8
827	Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. 2015 , 149, 1454-1461.e1	160
826	Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. 2015 , 59, 6807-15	35
825	Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. 2015 , 386, 1537-45	539
824	The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. 2015 , 13, 198	44
823	[S3 guideline hepatitis C addendum]. 2015 , 53, 320-34	37
822	[Direct-acting antiviral treatment of chronic hepatitis C infection]. 2015 , 157, 57-60	
821	Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. 2015 , 34, 1666-74	24
820	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. 2015 , 64, 1824-33	99
819	Regimens for the Hepatitis C Treatment-Naïve Patient. 2015 , 19, 619-27, v	3
818	Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation. 2015 , 22, 404-11	29

817	Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease. 2015 , 22, 352-60	5
816	What does the pharmacological future of treating chronic hepatitis C look like?. 2015 , 8, 605-22	4
815	Management of direct-acting antiviral agent failures. 2015 , 63, 1511-22	62
814	Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. 2015 , 19, 641-56, vi	7
813	High-resolution genetic profile of viral genomes: why it matters. 2015 , 14, 62-70	10
812	Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. 2015 , 71, 63-6	8
811	Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. 2015 , 53, 3039-41	11
810	Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. 2015 , 44, 825-43	16
809	Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States. 2015 , 61, 1054-62	21
808	Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. 2015 , 9, 1483-94	7
807	The safety of daclatasvir for the treatment of hepatitis C. 2015 , 14, 1787-97	2
806	European Code against Cancer 4th Edition: Infections and Cancer. 2015 , 39 Suppl 1, S120-38	30
805	Diagnosis and management of hepatitis C. 2015 , 76, 625-30	4
804	Daclatasvir for the treatment of chronic hepatitis C. 2015 , 16, 2679-88	6
803	Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. 2016 , 62, 440-447	30
802	Emerging treatments for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2015 , 114, 204-15	3,2 32
801	New era for management of chronic hepatitis C virus using direct antiviral agents: A review. 2015 , 6, 301-10	28
800	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 3 trial. 2015 , 385, 1087-97	239

799	New kids on the block--step by step to an ideal HCV therapy. 2015 , 385, 1050-2	9
798	Sofosbuvir, a New Nucleotide Analogue, for the Treatment of Chronic Hepatitis C Infection. 2015 , 31, 29-37	5
797	Hepatitis C virus-associated cancer. 2015 , 10, 345-70	66
796	Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. 2015 , 9, 21-30	4
795	Sofosbuvir for the treatment of hepatitis C virus infection. 2015 , 187, 203-204	3
794	Hepatitis C Virus. 2016 , 1313-1345	
793	Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. 2016 , 22, 863-71	1
792	Australian recommendations for the management of hepatitis C virus infection: a consensus statement. 2016 , 204, 268-72	49
791	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. 2016 , 2016, 4385643	14
790	Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?. 2017 , 9, e2017003	8
789	Ribavirin: Past, present and future. 2016 , 8, 123-30	35
788	The Role of Direct Acting Anti-Virals in Chronic Hepatitis C Treatment-2016 Update. 2016 , 8,	
787	A Protease Inhibitor with Induction Therapy with Natural Interferon- α In Patients with HCV Genotype 1b Infection. 2016 , 17, 350	1
786	Anti-Hepatitis Virus Agents. 2016 , 239-270	
785	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. 2016 , 8, 75-80	7
784	A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. 2016 , 18, e37094	7
783	Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4. 2016 , 22, 1437-1445	2
782	Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. 2016 , 12, 861-72	8

781	Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. 2016 , 29, 282-96	8
780	Advances in hepatitis C therapy: What is the current state - what come's next?. 2016 , 8, 139-47	75
779	Overview of Comprehensive Hepatitis C Virus Medication Management in a State Medicaid Program. 2016 , 22, 1161-6	1
778	Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. 2016 , 2016, 5743521	4
777	Recent Advances in Antiviral Therapy for Chronic Hepatitis C. 2016 , 2016, 6841628	39
776	Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin. 2016 , 13, 310-5	8
775	Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. <i>Viruses</i> , 2016 , 8, 91	6.2 16
774	Hepatitis C virus: Promising discoveries and new treatments. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6393-401	5.6 15
773	In Vitro Study on Anti-Hepatitis C Virus Activity of <i>Spatholobus suberectus</i> Dunn. 2016 , 21,	19
772	Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. 2016 , 1,	6
771	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. 2016 , 11, e0155934	26
770	Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis. 2016 , 11, e0157832	20
769	Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C. 2016 , 11, e0163945	3
768	Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. 2016 , 11, e0164691	46
767	Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance. 2016 , 11, e0165047	26
766	Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. 2016 , 16, e40959	48
765	Anti-hepatitis C virus drugs and kidney. 2016 , 8, 1343-1353	12
764	Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?. 2016 , 50, 252-7	5

763	Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1. 2016 , 95, e3004		22
762	Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient. 2016 , 57, 2693-5		
761	Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. 2016 , 64, 386-93		34
760	Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 857-865	3-4	41
759	Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. 2016 , 6, 119-45		18
758	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. <i>Hepatology</i> , 2016 , 63, 1112-9	11.2	56
757	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. <i>Liver International</i> , 2016 , 36, 42-8	7.9	43
756	Baseline HCV-RNA levels in genotype 1 chronic hepatitis C patients: The role of different cut-off points. <i>Hepatology</i> , 2016 , 64, 1385-6	11.2	1
755	Hepatitis C in Australian prisons: a national needs assessment. 2016 , 12, 3-16		7
754	Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 274-81	3-4	7
753	Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 217-26	3-4	40
752	High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 667-76	3-4	5
751	Host genetic variants influencing the clinical course of hepatitis C virus infection. 2016 , 88, 185-95		26
750	Disconnected by design: analytic approach in treatment networks having no common comparator. 2016 , 7, 420-432		16
749	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. 2016 , 31, 1323-9		21
748	Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 447-54	3-4	39
747	Pricey pills for an even pricier problem. 2016 , 122, 840-1		
746	Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. 2016 , 36, 562-74		8

745	Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 623-30	3.4	31
744	Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. <i>Hepatology</i> , 2016 , 63, 428-36	11.2	30
743	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. 2016 , 18, 22		13
742	Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. 2016 , 36, 203-17		19
741	Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. 2016 , 60, 5368-78		67
740	Hepatitis C-A clinical review. 2016 , 88, 1844-55		27
739	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. 2016 , 95, e2702		31
738	Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. <i>Infectious Diseases and Therapy</i> , 2016 , 5, 299-312	6.2	24
737	Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. 2016 , 22, 214-217		29
736	Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. <i>Antiviral Therapy</i> , 2017 , 22, 307-312	1.6	45
735	Ledipasvir and sofosbuvir for HCV infection in patients coinfecting with HBV. <i>Antiviral Therapy</i> , 2016 , 21, 605-609	1.6	39
734	Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia. 2016 , 12, 253-269		15
733	Genotype 1 hepatitis C virus and the pharmacist's role in treatment. 2016 , 73, 764-74		17
732	Drug Interactions Associated with HIV and HCV Medications. 2016 , 8, 404-415		
731	Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. 2016 , 6, 31777		52
730	Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis. <i>Antiviral Therapy</i> , 2017 , 22, 369-379	1.6	11
729	Les nouveaux traitements de l'hépatite C. 2016 , 2016, 65-73		
728	Cancer Prevention: Lessons Learned and Future Directions. 2016 , 2, 713-722		11

727	Hepatitis C. 2016 , 480-486		
726	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. 2016 , 19, 326-34		27
725	APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. 2016 , 10, 681-701		60
724	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. 2016 , 10, 947-955		15
723	Pharmacologic Therapies in Gastrointestinal Diseases. 2016 , 100, 827-50		15
722	Handbook of Hepatitis C. 2016 ,		1
721	Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. 2016 , 55, 1337-1351		55
720	Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. 2016 , 7, 391-402		9
719	JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. 2016 , 46, 129-65		48
718	An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. 2016 , 111, 808-16		75
717	Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. 2016 , 19, 795-805		16
716	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. 2016 , 60, 3786-93		29
715	Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. <i>Hepatology</i> , 2016 , 63, 1796-808	11.2	49
714	Prevention and management of treatment failure to new oral hepatitis C drugs. 2016 , 17, 1215-23		42
713	APASL consensus statements and recommendation on treatment of hepatitis C. 2016 , 10, 702-26		155
712	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. 2016 , 63, 291-9		44
711	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 338-51	24.2	122
710	HBsAg and anti-HCV screening in elderly hospitalized patients of a German tertiary referral centre. 2016 , 54, 231-7		6

709	Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies. 2016 , 494, 236-47		14
708	Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA. 2016 , 84, 7-11		6
707	RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies. 2016 , 79, 1605-1613		39
706	Management of HCV-Associated Liver Cirrhosis. 2016 , 32, 96-104		5
705	Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. 2016 , 16, 659-665		6
704	Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. 2016 , 1, 97-104		65
703	Safety of direct antiviral agents in the management of hepatitis C. 2016 , 15, 1643-1652		24
702	Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 478-85	2.2	20
701	Extrahepatic Manifestations of Chronic Hepatitis C Infection: a Review and Update. <i>Current Hepatology Reports</i> , 2016 , 15, 150-157	1	
700	2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. 2016 , 59, 7311-51		29
699	Global genotype distribution of hepatitis C viral infection among people who inject drugs. 2016 , 65, 1094-1103		51
698	Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. 2016 , 10, 789-98		13
697	New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 631-43	3.4	34
696	HCV-HIV co-infected patients: no longer a 'special' population?. <i>Liver International</i> , 2016 , 36 Suppl 1, 43-6	7.9	25
695	A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. 2016 , 30, 160-8		47
694	HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016 , 36, 488-502	7.9	4
693	Why I do not treat patients for mild disease. <i>Liver International</i> , 2016 , 36 Suppl 1, 13-20	7.9	4
692	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. 2016 , 151, 1131-1140.e5		166

691	Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. 2016 , 63, 1405-1411		78
690	Velpatasvir and sofosbuvir: How will we use a new drug when the old agents work well?. 2016 , 8, 39-42		
689	Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients. 2016 , 22, 1536-1543		42
688	Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. 2016 , 19, 544-51		31
687	The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. 2016 , 44, 856-65		65
686	Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). 2016 , 63, 1320-1324		60
685	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. <i>Hepatology</i> , 2016 , 64, 1049-56	11.2	91
684	Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. 2016 , 44, 728-37		10
683	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i> , 2016 , 64, 1893-1899	11.2	52
682	Hepatitis C Management in Patients with Hepatitis C and HIV Co-infection. <i>Current Hepatology Reports</i> , 2016 , 15, 158-166	1	
681	New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). 2016 , 15, 85-100		15
680	Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. 2016 , 61, 3108-3117		8
679	Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. 2016 , 65, S109-S119		43
678	Diagnostics in hepatitis C: The end of response-guided therapy?. 2016 , 65, S67-S81		19
677	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study. <i>Hepatology</i> , 2016 , 64, 1911-1921	11.2	44
676	Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. 2016 , 10, 1289-1303		4
675	Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing. 2016 , 214, 1687-1694		10
674	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. 2016 , 63, 1042-1048		45

673	Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3495-3505	5.1	19
672	Effect of Registries and Cohort Studies on HCV Treatment. 2016 , 151, 387-90		8
671	Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir. 2016 , 54, 1631-1640		28
670	Cardiohepatic Interactions: Implications for Management in Advanced Heart Failure. 2016 , 12, 349-61		9
669	Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. 2016 , 26, 408-434		32
668	Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. 2016 , 29, 1257-1265		9
667	Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. 2016 , 91, 341-347		20
666	Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. 2016 , 48, 2515-2518		2
665	Management of Direct-Acting Antiviral Failures in Chronic Hepatitis C Infection. <i>Current Hepatology Reports</i> , 2016 , 15, 296-306	1	1
664	Velpatasvir y sofosbuvir: ¿Por qué utilizar un fármaco nuevo si los antiguos funcionan bien?. 2016 , 8, S16-S19		
663	Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 727-729	2.2	3
662	Hepatitis C Treatment in HIV Coinfection: Approaches, Challenges, and Future Opportunities. 2016 , 8, 379-399		2
661	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. 2016 , 6, 354-10		5
660	[Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment]. 2016 , 54, 760-9		7
659	Hepatocellular carcinoma. 2016 , 2, 160-18		1274
658	A case of hepatitis C related cirrhosis with genotype 1b relapsed after combination therapy with Sofosbuvir and Ledipasvir. 2016 , 57, 391-396		1
657	Response to Valeur et al. and Farmer et al. 2016 , 111, 147-8		
656	Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening. <i>Antiviral Therapy</i> , 2016 , 21, 567-577	1.6	5

655	High serum HCV RNA in chronic hepatitis C patients coinfecting with HIV despite successful antiretroviral therapy. <i>Antiviral Therapy</i> , 2016 , 21, 489-494	1.6	6
654	Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report. 2016 , 16, 66		6
653	Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report. 2016 , 95, e5304		3
652	Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection. 2016 , 35, 1373		7
651	Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. 2016 , 95, e4151		56
650	Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. 2016 , 95, e4243		13
649	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. 2016 , 95, e5048		29
648	Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. <i>Hepatology</i> , 2016 , 64, 405-14	11.2	154
647	Management of HCV Infection. 2016 , 61-78		
646	[Chronic Hepatitis C - Therapeutic Options in 2016]. 2016 , 158 Suppl 1, 54-7		1
645	Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. 2016 , 151, 457-471.e5		170
644	Management of Neurologic Manifestations in Patients with Liver Disease. 2016 , 18, 37		7
643	From current status to optimization of HCV treatment: Recommendations from an expert panel. 2016 , 48, 995-1005		12
642	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. 2016 , 63, 528-31		11
641	Why Referring Physicians Rarely Diagnose Gastrointestinal Diseases. 2016 , 111, 905-6		
640	Hepatitis C virus treatment update [A new era of all-oral HCV treatment]. 2016 , 3, 153-160		10
639	Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. 2016 , 16, 45		17
638	Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility—a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy. 2016 , 111, 903-5		24

637	Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. 2016 , 22, 846-852		23
636	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. 2016 , 151, 501-512.e1		169
635	Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. <i>Hepatology</i> , 2016 , 63, 1090-101	11.2	63
634	Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. <i>Hepatology</i> , 2016 , 64, 370-80	11.2	154
633	Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 455-63	3-4	5
632	Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 644-51	3-4	2
631	Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial. <i>Infectious Diseases and Therapy</i> , 2016 , 5, 113-24	6.2	2
630	Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. 2016 , 16, 1474-9		158
629	Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. 2016 , 43, 674-96		107
628	Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. 2016 , 44, 400-10		58
627	Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. 2016 , 5, 273-9		3
626	Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury. 2016 , 111, 148-9		27
625	A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients. 2016 , 47, 184-94		7
624	Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?. 2016 , 14, 41-56		4
623	Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. 2016 , 64, 790-9		53
622	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. 2016 , 48, 251-261		11
621	High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. 2016 , 10, 310-9		47
620	New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. 2016 , 9, 287-302		27

619	Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. 2016 , 1008, 255-259		62
618	Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. 2016 , 57, 82-8		20
617	[Hepatitis C infection: Therapeutic strategies]. 2016 , 45, 495-508		1
616	Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. <i>Hepatology</i> , 2016 , 63, 437-44	11.2	53
615	No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA. <i>Hepatology</i> , 2016 , 63, 28-30	11.2	29
614	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. <i>Liver International</i> , 2016 , 36 Suppl 1, 47-57	7.9	174
613	Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. 2016 , 34, 741-50		11
612	Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. 2016 , 10, 419-29		3
611	Sofosbuvir and ledipasvir for HIV/HCV co-infected patients. 2016 , 17, 743-9		10
610	Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. 2016 , 32, 456-62		23
609	HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. 2016 , 64, 1232-9		54
608	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. 2016 , 62, 1228-1234		19
607	Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C. 2016 , 15, 549-57		2
606	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. 2016 , 65, 33-39		86
605	Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase inhibitor. 2016 , 120, 352-63		33
604	Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing. 2016 , 126, 81-9		13
603	Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. 2016 , 43, 161-172		28
602	Ideal oral combinations to eradicate HCV: The role of ribavirin. 2016 , 64, 215-25		34

601	Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. 2016 , 62, 280-288	41
600	Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. 2016 , 64, 292-300	34
599	The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. 2016 , 64, 486-504	337
598	Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. 2016 , 20, 58-66	13
597	HCV Prevalence in Asian Americans in California. 2017 , 19, 91-97	3
596	Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. 2017 , 20, 16-32	11
595	Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. 2017 , 52, 94-103	35
594	Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. 2017 , 7, 41660	19
593	Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. 2017 , 32, 1436-1442	26
592	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. 2017 , 55, 1131-1139	15
591	Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection. 2017 , 152, 1366-1371	35
590	Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. 2017 , 52, 986-991	24
589	Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System. 2017 , 77, 313-318	21
588	Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. 2017 , 89, 1248-1254	37
587	Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan. 2017 , 30, 252-257	7
586	Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. 2017 , 23, 198-206	20
585	Profile of Roche's cobas [®] HCV tests. 2017 , 17, 311-319	7
584	Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir. 2017 , 51, 543-547	6

583	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. 2017 , 32, 1754-1762		51
582	Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. <i>Hepatology</i> , 2017 , 66, 661-663	11.2	14
581	Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting. 2017 , 74, S1-S9		2
580	Treatment of Hepatitis C in Children. <i>Current Hepatology Reports</i> , 2017 , 16, 18-25	1	0
579	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. 2017 , 11, 188-198		2
578	Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. 2017 , 45, 1201-1212		43
577	Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 750-758	3.4	8
576	Future Paradigms of HCV Management with Resistance Testing. <i>Current Hepatology Reports</i> , 2017 , 16, 1-11	1	1
575	HCV management in resource-constrained countries. 2017 , 11, 245-254		8
574	Current therapy for chronic hepatitis C: The role of direct-acting antivirals. 2017 , 142, 83-122		111
573	Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. 2017 , 89, 51-56		5
572	Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. 2017 , 114, 2018-2023		18
571	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017 , 65, 1810-1822	11.2	64
570	Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. 2017 , 66, 1123-1129		38
569	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. 2017 , 66, 1138-1148		131
568	Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. 2017 , 2, 347-353		57
567	Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. 2017 , 6, 147-163		9
566	Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. 2017 , 11, 593-601		4

565	Colorectal cancer diagnosed during pregnancy: systematic review and treatment pathways. 2017 , 29, 743-753	25
564	Influence of genetic variations in the SOD1 gene on the development of ascites and spontaneous bacterial peritonitis in decompensated liver cirrhosis. 2017 , 29, 800-804	5
563	Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. 2017 , 37, 635-646	17
562	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. 2017 , 49, 731-741	14
561	Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics. 2017 , 107, 893-899	22
560	The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. 2017 , 29, 759-766	10
559	Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. 2017 , 4, 174-185	31
558	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. 2017 , 5, E97-E108	14
557	Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration. 2017 , 29, 781-785	3
556	Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations. 2017 , 1, 99-109	4
555	Endoscopic variceal ligation combined with argon plasma coagulation versus ligation alone for the secondary prophylaxis of variceal bleeding: a systematic review and meta-analysis. 2017 , 29, 621-628	6
554	Direct-acting antivirals: the endgame for hepatitis C?. 2017 , 24, 31-37	62
553	Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study. 2017 , 29, 951-955	6
552	Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. 2017 , 77, 1043-1055	31
551	Duodenal histopathology and laboratory deficiencies related to bone metabolism in coeliac disease. 2017 , 29, 897-903	12
550	The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 976-981	3-4 30
549	Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience. 2017 , 29, 979-980	10
548	Nonalcoholic fatty liver disease can be predicted by retinal vascular changes in patients with obesity without hypertension or diabetes. 2017 , 29, 962-967	3

547	Management of different types of gastric varices with band ligation: a 3-year experience. 2017 , 29, 968-972		2
546	Clinical experience and diagnostic algorithm of vulval Crohn's disease. 2017 , 29, 838-843		16
545	Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes. 2017 , 29, 879-884		13
544	Real-world effectiveness of ombitasvir/paritaprevir/ritonavir [±] dasabuvir [±] ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 936-943	3-4	37
543	A fixed-dose combination of ledipasvir and sofosbuvir [±] ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis. 2017 , 33, 348-360		
542	Small-bowel mucosal healing assessment by capsule endoscopy as a predictor of long-term clinical remission in patients with Crohn's disease: a systematic review and meta-analysis. 2017 , 29, 844-848		23
541	Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease. 2017 , 93, 92-98		36
540	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. 2017 , 46, 46-55		14
539	Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease. 2017 , 29, 909-915		11
538	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017 , 37, 662-668	7-9	16
537	NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. 2017 , 52, 845-854		40
536	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. 2017 , 66, 703-710		72
535	Belgian experience with direct acting antivirals in people who inject drugs. 2017 , 177, 214-220		26
534	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. 2017 , 2, 494-500		37
533	Hepatitis C infection: Updates on treatment guidelines. 2017 , 42, 14-23		1
532	Orthotopic liver transplantation changes the course of gastric antral vascular ectasia: a case series from a transplant center. 2017 , 29, 973-976		5
531	Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. 2017 , 1, 248-255		20
530	Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 966-975	3-4	16

529	Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China. 2017 , 96, e6830	10
528	Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. 2017 , 29, 777-780	11
527	Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. 2017 , 29, 946-950	4
526	Effectiveness and safety of ledipasvir/sofosbuvir-ribavirin in the treatment of HCV infection: The real-world HARVEST study. 2017 , 62, 387-392	18
525	HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. 2017 , 18, 126-134	29
524	Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. 2017 , 65, 864-866	7
523	Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. 2017 , 29, 826-830	13
522	Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. 2017 , 47, 1308-1316	33
521	The prevalence of viral agents in esophageal adenocarcinoma and Barrett's esophagus: a systematic review. 2017 , 29, 817-825	20
520	Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. 2017 , 29, 805-810	14
519	Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. 2017 , 45, 1427-1432	17
518	Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. 2017 , 29, 686-693	39
517	Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach. 2017 , 49, 778-781	8
516	Overcoming the resistance to resistance testing: Collecting the data. <i>Liver International</i> , 2017 , 37, 506-508	2
515	Treatment optimization for HIV/HCV co-infected patients. 2017 , 4, 18-36	13
514	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. 2017 , 49, 561-575	11
513	Urgency to treat patients with chronic hepatitis C in Asia. 2017 , 32, 966-974	18
512	Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. <i>Hepatology</i> , 2017 , 65, 1094-1103	11.2 49

511	Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. 2017 , 55, 56-71	19
510	NS5A inhibitors for the treatment of hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 180-186	3.4 20
509	The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. 2017 , 45, 455-467	15
508	Clinical efficacy of Rong-Yang-Jyh-Gan-Tang on patients with chronic hepatitis C: A double-blinded randomized placebo-controlled crossover study. 2017 , 196, 1-8	4
507	The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?. 2017 , 7, 10233	18
506	Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. 2017 , 46, 992-1000	45
505	Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. 2017 , 61,	5
504	[The news in hepatitis C therapy]. 2017 , 159, 43-52	
503	Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System. 2017 , 11, 1179546817713204	6
502	Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. 2017 , 92, 1349-1355	33
501	Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. 2017 , 11, 509-516	3
500	The potential of signal peptide peptidase as a therapeutic target for hepatitis C. 2017 , 21, 827-836	2
499	Direct-acting antivirals for chronic hepatitis C. 2017 , 9, CD012143	38
498	Ledipasvir+ Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis. 2017 , 49, 1855-1863	8
497	Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician. 2017 , 21, 659-672	4
496	Triplex High-Resolution Melting Assay for the Simultaneous Assessment of IFNL3 rs12979860, ABCB11 rs2287622, and RNF7 rs16851720 Genotypes in Chronic Hepatitis C Patients. 2017 , 19, 857-869	4
495	Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series. 2017 , 153, 1165-1166	6
494	Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?. 2017 , 51, 961-969	2

493	Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. 2017 , 40, 433-446		
492	Analytical and clinical performance of the Hologic Aptima HCV Quant Dx Assay for the quantification of HCV RNA in plasma samples. 2017 , 248, 159-165		8
491	Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. 2017 , 40, 433-446		12
490	Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. 2017 , 20, 1110-1120		11
489	Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. 2017 , 46, 540-548		29
488	Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. <i>Infectious Diseases and Therapy</i> , 2017 , 6, 423-433	6.2	11
487	Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals. 2017 , 153, 626-631		12
486	Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. 2017 , 96, e7568		24
485	Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. 2017 , 29, 767-776		13
484	Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity. 2017 , 96, e5914		38
483	Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. 2017 , 96, e6128		30
482	Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries". 2017 , 67, 1350-1352		5
481	Direct-acting antivirals for chronic hepatitis C. 2017 , 6, CD012143		33
480	Shortening the duration of therapy for chronic hepatitis C infection. 2017 , 2, 832-836		26
479	Novel treatments for chronic hepatitis C: closing the remaining gaps. 2017 , 37, 107-111		17
478	Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients. 2017 , 112, 1824-1831		15
477	Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial. 2017 , 21, 182-187		18
476	Doubling of coastal flooding frequency within decades due to sea-level rise. 2017 , 7, 1399		309

475	Drug interactions in HIV-infected patients treated for hepatitis C. 2017 , 13, 807-816		15
474	Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. 2017 , 144, 281-285		22
473	Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. 2017 , 9, 262-276		3
472	The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montr�al, Canada: a modelling study. 2017 , 17, 162		22
471	Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. 2017 , 32, 749-755		9
470	Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. 2017 , 64, 44-52		68
469	Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. 2017 , 6, 65-82		5
468	Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. 2017 , 30, 23-42		7
467	Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. <i>Hepatology</i> , 2017 , 65, 439-450	11.2	59
466	The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. <i>Hepatology</i> , 2017 , 65, 426-438	11.2	60
465	Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. 2017 , 13, 105-112		13
464	Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. 2017 , 389, 1268-1272		25
463	Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. <i>Liver International</i> , 2017 , 37, 5-18	7.9	62
462	The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit. <i>Liver International</i> , 2017 , 37, 345-353	7.9	20
461	Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. 2017 , 33, 11-21		14
460	Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. 2017 , 89, 284-290		47
459	Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. 2017 , 32, 1136-1142		24
458	EASL Recommendations on Treatment of Hepatitis C 2016. 2017 , 66, 153-194		821

457	Hepatitis C. 2017 , 628-698	
456	RE: Steatorrhea, Hyperoxaluria and Colonic Hyperproliferation After Roux-en-Y Gastric Bypass. 2017 , 153, 1166	
455	Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection. 2017 , 3, e229	4
454	Economic study of the value of expanding HCV treatment capacity in Germany. 2017 , 4, e000130	7
453	Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders. 2017 , 37, 127-130	6
452	Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital. 2017 , 28, 1333-1344	4
451	Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy. 2017 , 16, 366-374	2
450	Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C Infections. 2017 ,	
449	A Brief Update on the Treatment of Hepatitis C. 2017 ,	
448	Hemophilia gene therapy comes of age. 2017 , 2017, 587-594	13
447	Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C. 2017 , 9, 1179559X1771912	
446	Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. 2017 , 4, ofx024	20
445	Hepatitis C treatment: where are we now?. 2017 , 10, 39-52	64
444	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. 2017 , 18,	20
443	Treatment Options in Hepatitis C. 2017 , 114, 11-21	14
442	Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. 2017 , 13, 477-497	11
441	Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection. 2017 , 56, 787-790	9
440	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. 2017 , 4, ofw266	10

439	Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. 2017 , 12, e0169401		18
438	Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain. 2017 , 9, 7-11		1
437	Hepatitis C Virus Infection Treatment: Recent Advances and New Paradigms in the Treatment Strategies. 2017 ,		1
436	Prevalence of hepatitis B, hepatitis C and human immunodeficiency viruses, and evaluation of risk factors for transmission: Report of a population screening in Nigeria. 2017 , 107, 346-351		2
435	Hemophilia gene therapy comes of age. 2017 , 1, 2591-2599		42
434	Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. <i>World Journal of Gastroenterology</i> , 2017 , 23, 3163-3173	5.6	16
433	Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism. 2017 , 16, 207-214		17
432	Current Treatment of Chronic Hepatitis C. 2017 , 781-789		1
431	Optimizing Implementation of Hepatitis C Birth-Cohort Screening and Treatment Strategies: Model-Based Projections. 2017 , 2, 2381468316686795		3
430	Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients. 2017 , 1, 156-164		1
429	Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products. 2017 , 100, 976-984		18
428	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. 2018 , 16, 1811-1819.e4		16
427	Stability Indicating RP-HPLC Method for Estimation of Potential Impurities in Ledipasvir and Characterization of a New Degradation Impurity. 2018 , 56, 383-395		4
426	Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. 2018 , 15, 155-161		9
425	Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. 2018 , 19, 451-456		2
424	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. 2018 , 50, 569-583		13
423	Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. 2018 , 37, 17-39		122
422	Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1197-1207	3.4	22

421	No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. 2018 , 16, 927-935	10
420	Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. 2018 , 13, 775-790	2
419	Host-targeting therapies for hepatitis C virus infection: current developments and future applications. 2018 , 11, 1756284818759483	22
418	EASL Recommendations on Treatment of Hepatitis C 2018. 2018 , 69, 461-511	1079
417	Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. 2018 , 12, 126-132	15
416	Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. 2018 , 24, 524-530	6
415	Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir. 2018 , 57, 1369-1383	12
414	The role of external beam radiotherapy in the treatment of hepatocellular cancer. 2018 , 124, 3476-3489	16
413	Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). 2018 , 61, 4052-4066	28
412	Antiviral Agents. 2018 , 1551-1567.e6	3
411	Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. 2018 , 78, 245-256	14
410	Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. 2018 , 19, 299-307	30
409	All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. <i>Hepatology</i> , 2018 , 68, 32-47	11.2 52
408	Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals. 2018 , 35, 117-122	10
407	Is Hepatitis C Virus Elimination in Well-Defined Patient Groups Possible?. 2018 , 66, 1366-1367	4
406	Treatment of hepatitis C: Results in real life. <i>Liver International</i> , 2018 , 38 Suppl 1, 21-27	7.9 39
405	Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. 2018 , 33, 551-557	14
404	The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. 2018 , 47, 838-844	29

403	The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. 2018 , 53, 679-688		34
402	Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 631-639	3-4	8
401	Engineered Livers for Infectious Diseases. 2018 , 5, 131-144		28
400	The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 535-542	3-4	9
399	Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. 2018 , 66, 505-515		66
398	Advances in the treatment of HIV/HCV coinfection in adults. 2018 , 19, 49-64		40
397	Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam. <i>Antiviral Therapy</i> , 2018 , 23, 415-423	1-6	14
396	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. 2018 , 66, 1742-1750		20
395	Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. 2018 , 217, 1033-1043		19
394	Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients. 2018 , 6, E12-E18		6
393	Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 870-873	3-4	18
392	Treatment of hepatitis C in special populations. 2018 , 53, 591-605		20
391	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. 2018 , 5, ofy001		27
390	The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development. <i>Current Hepatology Reports</i> , 2018 , 17, 97-104	1	
389	Treatment of HCV in the Department of Corrections in the Era of Oral Medications. 2018 , 24, 127-136		17
388	Undiagnosed HIV and HCV Infection in a New York City Emergency Department, 2015. 2018 , 108, 652-658		17
387	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. 2018 , 67, 1010-1017		98
386	Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy. 2018 , 16, 203-214		13

385	Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors. 2018 , 11, 525-529		17
384	Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 205-208	3-4	4
383	Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. 2018 , 67, 460-463		39
382	Real-world challenges for hepatitis C virus medications: a critical overview. 2018 , 44, 143-160		14
381	Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. 2018 , 6, 213-224		16
380	Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). <i>Journal of Viral Hepatitis</i> , 2018 , 25, 37-46	3-4	4
379	In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. <i>Liver International</i> , 2018 , 38, 258-265	7-9	29
378	Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. 2018 , 66, 376-384		49
377	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 228-235	3-4	9
376	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. <i>Liver International</i> , 2018 , 38, 1010-1021	7-9	8
375	A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects. 2018 , 7, 641-651		4
374	Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. 2018 , 31, 1-13		11
373	Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. 2018 , 183, 118-126		105
372	Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus. 2018 , 454, 15-26		3
371	Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. <i>Hepatology</i> , 2018 , 67, 492-504	11.2	44
370	Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease. 2018 , 66, 464-474		1
369	Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 126-133	3-4	4
368	Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. 2018 , 90, 907-918		13

367	Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection – HIV-1 Co-Infection. 2018 , 38, 239-247		8
366	Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). 2018 , 21, 612-621		5
365	Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. <i>Hepatology</i> , 2018 , 67, 2430-2448	11.2	28
364	Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. 2018 , 47, 259-267		30
363	Management of Chronic Hepatitis C in End-stage Renal Disease. 2018 , 52, 287-294		2
362	Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. <i>Hepatology</i> , 2018 , 67, 847-857	11.2	43
361	Direct-acting antiviral agents in the treatment of chronic Hepatitis C - "Real-life" experience from an academic centre and two specialized clinical practices. 2018 , 56, 351-360		3
360	Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. 2018 , 68, 663-671		34
359	Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection. 2018 , 66, 425-427		24
358	Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 214-215	3.4	5
357	Safety, Tolerability, and Associated Side Effects of Direct- Acting Antivirals. 2018 ,		
356	Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. 2018 , 17, 18-32		20
355	2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. 2018 , 24, 169-229		24
354	Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfecting patients: insights from the German Hepatitis C-Registry. 2018 , 19, 225-234		
353	Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. 2018 , 30, 1200-1207		12
352	Interferon-Free Regimen for Hepatitis C: Insight and Management. 2018 , 28, 373-384		
351	AN INNOVATIVE METHOD DEVELOPMENT AND FORCED DEGRADATION STUDIES FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND LEDIPASVIR BY RP HPLC. 2018 , 34-41		
350	2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis C: What's New?. 2018 , 71, 315		

349	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). 2018 , 41, 597-608		10
348	Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?. 2018 , 11, 1756284818812358		8
347	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. 2018 , 13, e0209299		7
346	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). 2018 , 41, 597-608		
345	Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. 2018 , 13, e0205186		8
344	Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients. <i>Antiviral Therapy</i> , 2019 , 24, 11-17	1.6	1
343	Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA . 2018 , 63, 3480-3486		3
342	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. 2018 , 8, 14905		4
341	Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir. 2018 , 2, 1172-1178		10
340	Epidemiology and Elimination of HCV-Related Liver Disease. <i>Viruses</i> , 2018 , 10,	6.2	36
339	Expert opinion on the management of hepatitis C infection in Kuwait. 2018 , 10, 117-132		2
338	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. 2018 , 10, 595-602		10
337	Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men. 2018 , 5, ofy238		7
336	Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. 2018 , 15, 466-474		11
335	Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. 2018 , 67, 1477-1492		344
334	Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now. 2018 , 67, 1493-1497		36
333	Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial. 2018 , 19, 383		6
332	Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. 2018 , 57, 1101-1104		3

331	Management of acute HCV infection in the era of direct-acting antiviral therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 412-424	24.2	45
330	Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic. 2018 , 34, 690-698		5
329	The Mexican consensus on the treatment of hepatitis C. 2018 , 83, 275-324		9
328	Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. 2018 , 66, 1339-1345		6
327	Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. 2018 , 57, 1533-1542		
326	Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection. <i>Antiviral Therapy</i> , 2018 , 23, 585-592	1.6	1
325	Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. 2018 , 4, 17		4
324	Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling. 2018 , 9, 1546		34
323	Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1481-1492	3.4	6
322	Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population. 2018 , 24, 591-597		5
321	Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients. 2018 , 19, 979-995		0
320	Poor response to direct-acting antiviral therapy in HCV-infected elderly population: a real-life cohort study based on GeneXpert [®] technology. 2018 , 13, 467-474		3
319	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1429-1437	3.4	14
318	Characterization of and Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. <i>Viruses</i> , 2018 , 10,	6.2	7
317	Poor glycemic control and abrupt onset of diabetes in HCV patients receiving direct-acting antiviral drugs: case series. 2018 , 13, 525-528		2
316	Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population. 2018 , 63, 3233-3240		2
315	Electrochemical Method for the Determination of Three New Anti-Hepatitis C Drugs: Application in Human Blood Serum. 2018 , 165, B442-B451		20
314	Hepatitis C and HIV Coinfection in Developing Countries. 2018 , 135-155		1

313	Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. 2018 , 69, 1178-1187		70
312	Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfecting and HCV monoinfected patients. 2018 , 30, 1507-1511		6
311	Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population. 2018 , 133, 452-460		35
310	Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection. 2018 , 155, 1646-1647.e2		
309	Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C. 2018 , 2, 884-892		8
308	Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. 2018 , 8, 12266		10
307	The Mexican consensus on the treatment of hepatitis C. 2018 , 83, 275-324		
306	Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. 2018 , 46, 761-783		15
305	Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data. 2018 , 24, 23-28		4
304	Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. 2018 , 11, 295-298		29
303	Hepatitis C among vulnerable populations: A seroprevalence study of homeless, people who inject drugs and prisoners in London. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1260-1269	3-4	16
302	Real-world effectiveness of elbasvir/grazoprevir in HCV-infected patients in the US veterans affairs healthcare system. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1270-1279	3-4	24
301	Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1280-1286	3-4	9
300	Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. 2018 , 14, 649-657		3
299	The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. 2018 , 190, E677-E687		62
298	Hepatitis C. 2018 , 436-467		
297	Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. 2019 , 13, e1800006		1
296	Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. 2019 , 32, 655-663		7

295	[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents]. 2019 , 90, 141-147		5
294	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. 2019 , 34, 364-369		20
293	Prevention Strategies for Hepatocellular Carcinoma. 2019 , 255-289		1
292	Hepatocellular Carcinoma. 2019 ,		1
291	Kinetics and mechanism of the oxidative degradation of sofosbuvir by N-bromosuccinimide in aqueous medium. 2019 , 1, 1		
290	Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives. 2019 , 6, ofz128		5
289	Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. 2019 , 157, 692-704.e9		19
288	Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1249-1256	3-4	10
287	Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. 2019 , 39, 857-864		2
286	Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Mono-infection Associated with a High Risk of Acute Liver Failure. 2019 , 58, 2969-2975		1
285	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. 2019 , 157, 1506-1517.e1		19
284	Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single-centre experience. 2019 , 25, 1028-1034		5
283	Hepatitis C. 2019 , 394, 1451-1466		155
282	Epidemiological and Clinical Characteristics of Human Hepatitis C Virus Infection in Patients With Hepatitis C. 2019 , 6, ofz329		4
281	The Evolving Landscape of Liver Cirrhosis Management. 2019 ,		
280	Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1404-1412	3-4	11
279	A controlled clinical trial of ultraviolet blood irradiation (UVBI) for hepatitis C infection. 2019 , 6, 1614286		1
278	Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. 2019 , 51, 2295-2304		3

277	Thalassemia and hepatocellular carcinoma: links and risks. 2019 , 10, 323-334		6
276	The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®). 2019 , 237-280		1
275	Comorbid hepatitis C does not modulate prevalence or severity of diabetic retinopathy. 2019 , 13, 1681-1687		
274	Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. 2019 , 25, 944-950		10
273	Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system. 2019 , 34, 2173-2178		0
272	Viral Hepatitis: Chronic Hepatitis C. 2019 ,		1
271	Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients. 2019 , 65-95		
270	Updates on Heart Transplantation. 2019 , 16, 150-156		25
269	Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. 2019 , 2, e194765		18
268	What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?. 2019 , 39, 618-626		2
267	Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. 2019 , 39, 539-546		2
266	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. 2019 , 58, 1237-1263		34
265	Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi and Epclusa. 2019 , 29, 2415-2427		17
264	Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks. 2019 , 79, 30-35		4
263	Utility of viral kinetics in HCV therapy - It is not over until it is over?. <i>Liver International</i> , 2019 , 39, 815-817.9		3
262	Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in Iranian population. 2019 , 43, 594-602		4
261	Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1105-1116	3-4	12
260	Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 980-990	3-4	19

259	Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. 2019 , 39, 354-368	21
258	Viral infections after allogeneic hematopoietic stem cell transplant. 2019 , 2, e43	1
257	Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C. 2019 , 32, 189-194	1
256	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. 2019 , 220, 557-566	10
255	Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents. 2019 , 90, 141-147	
254	Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and Sofosbuvir. 2019 , 6, ofz087	
253	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. 2019 , 19, 300	2
252	Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. 2019 , 14, e0214795	21
251	An update on the management of hepatitis C virus and human immunodeficiency virus co-infection. 2019 , 14, 185-195	
250	Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. 2019 , 156, 987-996.e8	66
249	Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis. 2019 , 22, 592-598	3
248	Hepatitis C: Treatment. 2019 , 454-469	
247	Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting. 2019 ,	1
246	The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni® . 2019 , 57-80	0
245	The Evolution of Clinical Trials for Hepatitis C. 2019 , 187-235	
244	Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study. 2019 , 9, e026464	3
243	A Randomized Controlled Trial to Assess the Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients. 2019 , 13, 2089-2100	10
242	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. 2019 , 14, e0224751	1

241 Real-World Evidence and Hepatitis C. **2019**, 411-427

240 Viral hepatitis C treatment shortening - what is the limit?. **2019**, 5, 265-270

3

239 Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. **2019**, 14, e0218759

8

238 Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. **2019**, 31, 1004-1009

9

237 International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. **2019**, 103, 733-746

1

236 Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort. *Liver International*, **2019**, 39, 90-97

7.9 4

235 Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. **2019**, 156, 431-445

74

234 Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virus-infected donors into hepatitis C virus-negative patients. **2019**, 32, 179-186

5

233 Liver and Gastrointestinal Pharmacology. **2019**, 645-656

232 Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community. **2019**, 21, 549-554

1

231 Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016. **2019**, 56, 8-16

4

230 The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA. *Hepatology*, **2019**, 70, 476-486

11.2 36

229 Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. **2019**, 259, 54-61

4

228 Evolution of efficacious pangenotypic hepatitis C virus therapies. **2019**, 39, 1091-1136

10

227 Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. **2019**, 208, 3-24

11

226 Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. *Hepatology*, **2019**, 69, 1861-1872

11.2 43

225 Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. **2019**, 68, 721-728

22

224 Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. **2020**, 53, 569-577

14

223	Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. 2020 , 70, 1900-1906		38
222	Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients. 2020 , 65, 1385-1395		4
221	Prognostic Analysis of Hepatocellular Carcinoma With Hepatitis C Virus Infection Using Epithelial-Mesenchymal Transition Gene Profiles. 2020 , 245, 302-308		1
220	Hepatitis C Treatment Differences in Elderly Patients: Single-Center Retrospective Study. 2020 , 54, 113-121		2
219	Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 243-260	3-4	10
218	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 712-719	3-2	2
217	Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States. 2020 , 68, 379-387		6
216	Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. 2020 , 1-6		9
215	Engagement in the Hepatitis C care continuum among people who use drugs. 2020 , 25, 343-349		0
214	Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. <i>Liver International</i> , 2020 , 40, 319-323	7-9	5
213	Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era. 2020 , 135, 107-113		3
212	Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 371-375	3-4	4
211	Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?. 2020 , 54, 192-199		8
210	Comparing direct acting antivirals for hepatitis C using observational data - Why and how?. 2020 , 8, e00650		2
209	High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1593-1600	3-2	2
208	Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. 2020 , 58, 1110-1131		3
207	Association of human immunodeficiency virus and hepatitis C virus infection with long-term outcomes post-ST segment elevation myocardial infarction in a disadvantaged urban community. 2020 , 311, 60-66		1
206	Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa. <i>Liver International</i> , 2020 , 40, 2643-2654	7-9	

205	Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. 2020 , 213, 108116		2
204	Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. 2020 , 1, e200-e208		28
203	Screening for Hepatitis C Virus: How Universal Is Universal?. 2020 , 42, 1434-1441		5
202	Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation. 2021 , 51, 1927-1934		1
201	Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. 2020 , 34, 1699-1711		7
200	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. 2020 , 222, S745-S757		4
199	Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. 2020 , 7, 347-360		5
198	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1019-1040	3.2	27
197	Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment. 2020 , 54, 1057-1064		1
196	Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. <i>Liver International</i> , 2020 , 40, 1853-1859	7.9	7
195	Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfecting with HIV and HCV: Real world data in a black population. 2020 , 99, e19140		
194	HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic. 2020 , 35, 1477-1483		8
193	Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. 2020 , 20, 47		11
192	HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. 2020 , 10, 325		5
191	Management of hepatitis B and hepatitis C coinfection: an expert review. 2020 , 18, 1033-1044		2
190	Hepatitis c virus and chronic kidney disease. 2020 , 14, 579-590		5
189	Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. 2020 , 60, 1243-1252		2
188	Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study. 2020 , 165, 2193-2203		2

187	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. 2020 , 7, ofaa040	11
186	Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. 2020 , 15, e0229517	4
185	Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. 2020 ,	28
184	WITHDRAWN: The next frontier: universal hepatitis C virus screening in pregnant women. 2020 ,	
183	HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. 2020 , 15, e0224875	3
182	Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity. 2020 , 597, 113642	2
181	Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. 2021 , 66, 881-898	0
180	Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study. 2021 , 93, 3752-3760	3
179	The effectiveness and safety of sofosbuvir-ledipasvir for patients with hepatitis C virus genotype 2 infection. 2021 ,	
178	A Population-Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection. 2021 , 5, 387-399	2
177	Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 129-141	3-4 2
176	Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. 2021 , 1322, 139-157	2
175	On the possibility of eradicating hepatitis C in Russia. 2021 , 39, 31	
174	Are Hepatitis C Positive Female Liver Transplant Recipients Still at Increased Risk for Graft Failure? Re-Examining the Disparity in the Modern Era of Direct Acting Antiviral Agents. 2021 ,	
173	Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature. 2021 , 22, 89-98	0
172	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'Liver Network Activity' (LINA) cohort update results. 2021 , 15, 1057-1063	
171	Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report. 2021 , 21, 389	0
170	Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. 2021 , 16, e0249770	3

169	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 982-993	3.4	0
168	Viral hepatitis: A brief introduction, review of management, advances and challenges. 2021 , 9, 139-151		
167	Hepatitis C: A Pharmacological Therapeutic Update. 2021 , 10,		4
166	Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. 2021 ,		0
165	Blinding in Clinical Trials for Chronic Liver Diseases. 2021 , 41, 163-171		0
164	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , 2021 , 41, 2179-2188	7.9	1
163	Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. 2021 , 116, 1924-1928		1
162	Efficacy of Direct-Acting Antiviral Combination Therapy in the Treatment of Hepatitis C Virus Among Kidney Transplant Patients. 2021 , 19, 169-173		
161	Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. 2021 , 18, 69		2
160	Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?. 2021 , 107, 166-169		0
159	Analysis of Clinical Trials of New Drugs for Liver Diseases in China. 2021 , 15, 3181-3191		1
158	An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. 2021 , 22, 1839-1846		
157	Evaluation of cure rate in patients with hepatitis C virus completing shortened courses of treatment. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021 ,	1.7	
156	Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. 2021 , 75, 547-556		10
155	Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. 2021 , 61, 369-376		6
154	The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophiliaHCC after HCV eradication in hemophilia. 2021 , 27, 100545		0
153	On the Possibility of Eradicating Hepatitis C in Russia. 2021 , 36, 27-38		
152	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. 2019 , 1911, 3-32		52

151	Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. 2017 , 553-627		0
150	Harvoni: A Combination Therapy for Curing HCV. 2017 , 558-582		2
149	Hepatitis C virus infection and new treatment strategies. 2019 , 37 Suppl 1, 15-19		1
148	Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study. 2021 , 72, 95-100		2
147	Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US. 2020 , 52, 1592-1602		4
146	No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 808-813	3-4	6
145	Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 987-995	3-4	6
144	Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritransplant Setting: A Case Report. 2016 , 17, 605-10		1
143	Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. 2017 , 6, 620		0
142	Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. 2019 , 4, 132		14
141	Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. 2014 , 9, e110857		13
140	Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. 2015 , 10, e0122844		31
139	Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. 2015 , 10, e0135645		51
138	Drug Pricing Evolution in Hepatitis C. 2016 , 11, e0157098		14
137	Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. 2016 , 11, e0159976		6
136	Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. 2017 , 12, e0170933		7
135	Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. 2017 , 12, e0175189		15
134	Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. 2017 , 12, e0184654		9

133	Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies. 2015 , 3, 36-41		7
132	Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. 2015 , 3, 140-8		23
131	Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy. 2015 , 3, 134-9		26
130	Hepatitis C in Canada and the importance of risk-based screening. 2016 , 42, 57-62		9
129	Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature. 2017 , 8, 22299-22303		7
128	Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. 2018 , 9, 5509-5513		5
127	Ledipasvir with sofosbuvir. 2015 , 38, 219-21		4
126	C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients. 2016 , 4, S12		6
125	Hepatitis C Virus: Efficacy of New DAAs Regimens. 2020 , 20, 143-149		12
124	Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study. 2020 , 9, e16863		4
123	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. 2015 , 21, 358-64		11
122	Therapy Implications of Hepatitis C Virus Genetic Diversity. <i>Viruses</i> , 2020 , 13,	6.2	13
121	Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7412-26	5.6	35
120	Impact of new treatment options for hepatitis C virus infection in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10760-75	5.6	23
119	Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10776-82	5.6	14
118	Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10811-23	5.6	35
117	Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6573-81	5.6	20
116	Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. <i>World Journal of Gastroenterology</i> , 2016 , 22, 1650-63	5.6	34

115	Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9044-9056	5.6	6
114	Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2016 , 22, 2844-54	5.6	4
113	Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA World Journal of Gastroenterology, 2017 , 23, 4759-4766	5.6	13
112	Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. <i>World Journal of Gastroenterology</i> , 2017 , 23, 8120-8127	5.6	6
111	Hepatitis C virus infection in children in the era of direct-acting antiviral. <i>World Journal of Gastroenterology</i> , 2018 , 24, 2555-2566	5.6	14
110	Discontinuation of new hepatitis C drugs among Medicare patients. 2020 , 26, 84-88		2
109	Treatment of Chronic Hepatitis C Using Newly Developed Oral Antiviral Agents. 2015 , 88, 635		1
108	The new era of hepatitis C virus therapy. 2015 , 21, 345-54		2
107	SASLT guidelines: Update in treatment of Hepatitis C virus infection. 2016 , 22 Suppl, S25-57		15
106	Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. 2017 , 146, 23-33		11
105	Predictive factors associated with hepatitis C antiviral therapy response. 2015 , 7, 1617-31		58
104	New treatment strategies for hepatitis C infection. 2015 , 7, 2100-9		18
103	Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. 2015 , 7, 2209-13		8
102	All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. 2015 , 7, 2363-8		10
101	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. 2015 , 7, 2543-50		8
100	Update on hepatitis C: Direct-acting antivirals. 2015 , 7, 2829-33		18
99	Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. 2015 , 7, 725-37		42
98	Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. 2015 , 7, 806-13		42

97	Chronic hepatitis C: This and the new era of treatment. 2016 , 8, 92-106	57
96	Sofosbuvir treatment and hepatitis C virus infection. 2016 , 8, 183-90	11
95	Is the 25-year hepatitis C marathon coming to an end to declare victory?. 2017 , 9, 921-929	5
94	Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients. 2017 , 9, 1190-1196	1
93	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. 2017 , 9, 352-367	37
92	Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. 2017 , 11, 711-720	5
91	Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. 2017 , 11, 721-727	9
90	The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?. 2020 , 31, 384-392	2
89	Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. 2020 , 31, 148-155	2
88	Hepatitis C Screening: The Downstream Dissemination of Evolving Guidelines in a Resident Continuity Clinic. 2017 , 9, e1441	1
87	Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection. 2018 , 8, 116-121	4
86	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. 2021 , 144, 112276	3
85	Neue Arzneimittel 2014. 2015 , 37-198	3
84	Treatment of Recurrent Hepatitis C. 2016 , 55-77	
83	Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. 2016 , 4, 97-112	4
82	Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. 2016 , 3, 58-69	
81	A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. 2016 , 5, 2061	1
80	A Belgian Randomized Trial in Hepatitis C Virus-Infected Patients with Persistently Normal Alanine Aminotransferase. 2016 , 1, 001-004	

- 79 Is the 25-year hepatitis C marathon coming to an end to declare victory?.
- 78 Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C - A Review. **2017**, 7,
- 77 Treatment of Hepatitis C. **2018**, 446-463.e3
- 76 Chronische Hepatitis. **2018**, 433-445
- 75 Generic Sofosbuvir/Ledipasvir for Treatment of Naïve, Non-Cirrhotic, Easy to Treat Patients with Chronic Hepatitis C Genotype 4: 8 Vs. 12 Weeks of Treatment. **2018**, In Press,
- 74 Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. **2017**, 6, 620 1
- 73 Chronic Hepatitis C. **2019**, 75-87
- 72 Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. **2019**, 25, 55-60 4
- 71 Antifibrotic Therapy for Liver Cirrhosis. **2019**, 167-189
- 70 Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. *World Journal of Gastroenterology*, **2019**, 25, 3897-3919 5.6 1
- 69 Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study (Preprint).
- 68 Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection. **2019**, 3, 027-030
- 67 Efficacy of Posttransplant Ledipasvir-Sofosbuvir in the Treatment of Patients Who Have Undergone Chronic Hepatitis C-Related Liver Transplant. **2020**, 0
- 66 Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey. **2020**, 31, 239-245 1
- 65 Hepatitis C: How Good Are Real-Life Data and Do Generics Work. **2020**, 49, 279-299
- 64 Quercetin and its derivatives as antiviral potentials: A comprehensive review. **2021**, 22
- 63 Interferon-free anti-viral therapy for chronic hepatitis C. **2020**, 16-21
- 62 ERKRANKUNGEN DER VERDAUUNGSORGANE. **2020**, pA-1-pA7.8-14

61	Is ribavirin alive or dead in the current era of HCV therapy?. 2020 , 35-40		
60	Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider?. 2020 , 59-65		
59	Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C. 2020 , 28, e755-e757		1
58	Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. <i>P and T</i> , 2014 , 39, 345-52	1.4	11
57	Sofosbuvir: a novel oral agent for chronic hepatitis C. 2014 , 27, 331-337		56
56	A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver □ April 9-13, 2014 □ London, United Kingdom Special Reporting on: □ SAPPHERE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin for Treatment of Experienced Adult With Hepatitis C Virus Genotype 1 □ All Genotypes	0.7	44
55	Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. <i>P and T</i> , 2015 , 40, 256-261		36
54	Hepatitis C (chronic). <i>Clinical Evidence</i> , 2015 , 2015,		
53	A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 □ Boston, Massachusetts Special Reporting on: □ Evaluation of Sofosbuvir and	0.7	19
52	A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver □ April 22-26, 2015 □ Vienna, Austria Special Reporting on: □ Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3	0.7	85
51	Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection. <i>American Health and Drug Benefits</i> , 2015 , 8, 54-8	1.7	8
50	New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 458-66	0.7	11
49	Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. <i>North American Journal of Medicine & Science</i> , 2016 , 9, 47-54		33
48	HCV cure for everyone or which challenges remain?. <i>Journal of Virus Eradication</i> , 2015 , 1, 55-8	2.8	1
47	Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 294-346	0.7	4
46	Roadblocks to Accessing Direct-Acting Antiviral Agents for Treatment of Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2015 , 11, 331-3	0.7	
45	A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus Genotype 1. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 815-7	0.7	3
44	Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population. <i>American Health and Drug Benefits</i> , 2016 , 9, 327-335	1.7	4

43	The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 1-11	0.7	5
42	New Therapies for Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 22-31	0.7	12
41	Hepatitis C in a New Era: A Review of Current Therapies. <i>P and T</i> , 2017 , 42, 316-329	1.4	28
40	CROI 2015: Highlights of Viral Hepatitis Therapy. <i>Topics in Antiviral Medicine</i> , 2015 , 23, 66-76	3.2	1
39	Changing Treatment Landscape of Hepatitis C Virus Infection Among Penitentiary Inmates. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2016 , 33, 14S-17S	0.7	
38	New Treatments for Hepatitis C. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2015 , 32, 25S-31S	0.7	
37	Treatment of Comorbid HIV/HCV. 2022 , 477-497		
36	Viral Hepatitis B and C. Cure or Treatment?. <i>Thalassemia Reports</i> , 2014 , 4, 43-50	2	
35	Oral antivirals in treatment naïve chronic hepatitis C infection.. <i>Hepatology</i> , 2022 ,	11.2	
34	Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial.. <i>Oxidative Medicine and Cellular Longevity</i> , 2022 , 2022, 9199190	6.7	1
33	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.. <i>Journal of the Formosan Medical Association</i> , 2022 ,	3.2	
32	Addressing Chronic HCV in People Who Inject Drugs and Inmates Is Necessary to Achieve HCV Elimination. <i>Current Hepatology Reports</i> , 2022 , 21, 1	1	
31	Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.. <i>Liver International</i> , 2022 ,	7.9	1
30	Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	
29	The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir.. <i>Viruses</i> , 2022 , 14,	6.2	1
28	Preferred Therapy for Specific Viral Pathogens. 2022 , 173-189		
27	Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.. <i>BMC Health Services Research</i> , 2022 , 22, 303	2.9	1
26	Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.. <i>Viruses</i> , 2022 , 14,	6.2	0

25	Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan.. <i>Medicina (Lithuania)</i> , 2022 , 58,	3.1	0
24	Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (≥65 years old): A Systematic Review and Meta-Analysis.. <i>Journal of Viral Hepatitis</i> , 2022 ,	3.4	
23	Viral hepatitis: Past, present, and future.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 1405-1429	5.6	0
22	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.. <i>Infectious Diseases and Therapy</i> , 2021 , 11, 485	6.2	0
21	The curing regimens of HCV: A SWOT analysis.. <i>Antiviral Therapy</i> , 2022 , 27, 13596535211072672	1.6	0
20	Pharmacist-led drug therapy management for Hepatitis C at a Federally qualified healthcare center. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022 ,	1.7	0
19	Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. <i>Diagnostics</i> , 2022 , 12, 1187	3.8	
18	Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study. <i>Korean Journal of Internal Medicine</i> ,	2.5	0
17	Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> ,	24.2	5
16	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BAiT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> ,	2.2	0
15	Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> ,	2.2	
14	Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells. <i>Aging</i> ,	5.6	
13	Impact of an Accelerated Pretreatment Evaluation on Linkage-to-Care for Hepatitis C-infected Persons Who Inject Drugs. 2022 , 16, 117822182211190		0
12	Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD. 1-14		1
11	Global research trends in the field of liver cirrhosis from 2011 to 2020: A visualised and bibliometric study. 2022 , 28, 4909-4919		0
10	Healthcare resource utilization in Hepatitis C-infected patients completing eight versus twelve weeks of treatment: A retrospective cohort study. 1,		0
9	Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study. 2022 ,		0
8	Identifying barriers and facilitators of the inclusion of pregnant individuals in hepatitis C treatment programs in the United States. 2022 , 17, e0277987		0

- 7 Antiviral Agents. **2023**, 1583-1598.e6
- 6 ?????????? C ??????. ?????????????? ?????? ?????? (????????????????). **2022**, 22-28
- 5 Current Landscape of HCV Therapeutics. **2023**, 142-174
- 4 Conquering C [Going Beyond Cure. 42-51
- 3 Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus.
- 2 Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. 29, 949-966
- 1 Preferred Therapy for Specific Viral Pathogens. **2023**,